Our Science & Pipeline
Condensates are membraneless organelles in cells that are comprised of proteins and nucleic acids. These biomolecular assemblies are involved in many cellular processes fundamental to cellular homeostasis. Perturbations of condensates can lead to a variety of diseases including cancer and neurological disorders.
LEADING SCIENCE
The pillars of our proprietary platform
We are focused on well-understood & clearly defined condensate systems including oncogenic signaling hubs & transcriptional assemblies, and RNA foci. These condensate systems sequester key biomolecules, causing disease via two mechanisms: 1) accelerating oncogenic reactions, or 2) loss of function for these biomolecules. Our objective is to dissolve these condensates, releasing the sequestered biomolecules and restoring a healthy state.
Our technology and IP (derived from the Weitz lab at Harvard University and the Knowles lab at University of Cambridge) allow us to identify small molecules that dissolve condensates, and to identify novel & optimal binding mechanisms of action to drive drug discovery.
PhaseScanTM
We employ a multidimensional, microfluidics-based high throughput molecular screen to identify hits, determine their binding mechanisms of action, and drive drug discovery.
CelPhaseTM
We use state-of-the-art high-content cellular imaging to visualize condensates in disease cell models and patient samples, which enables target validation and confirming cellular target engagement for our chemical matter.
DeePhaseTM
Our proprietary ML/AI engine is foundational to everything we do. We use proprietary datasets from PhaseScan, CelPhase, biochemical/biophysical assays and genomics to build our models. We then apply these models across our drug discovery activities – including in target discovery, hit identification, indication selection.
Pipeline
